Vivos Therapeutics (VVOS) Receivables (2019 - 2026)

Vivos Therapeutics (VVOS) has 8 years of Receivables data on file, last reported at $1.8 million in Q1 2026.

• On a quarterly basis, Receivables rose 150.7% year-over-year to $1.8 million in Q1 2026; TTM through Mar 2026 was $1.8 million, a 150.7% increase from a year earlier, with the FY2025 full-year figure at $1.6 million, up 272.09% from the prior year.
• Receivables for Q1 2026 stood at $1.8 million, up from $1.6 million in the prior quarter.
• Over the last five years, Receivables for VVOS reached as high as $2.1 million in Q3 2025 and fell as low as $202000.0 in Q4 2023.
• Historically, Receivables has averaged $815529.4 across 5 years, with a median of $525000.0 in 2024.
• Across the five-year window, Receivables tumbled 77.41% in 2022 and jumped 370.04% in 2025, its largest moves.
• Year by year, Receivables stood at $457000.0 in 2022, then plunged by 55.8% to $202000.0 in 2023, then surged by 112.87% to $430000.0 in 2024, then jumped by 267.67% to $1.6 million in 2025, then grew by 13.85% to $1.8 million in 2026.
• Per Business Quant data, the three most recent Receivables figures were $1.8 million in Q1 2026, $1.6 million in Q4 2025, and $2.1 million in Q3 2025.